Trial Summary


This randomised double-blind, controlled phase 4 trial will compare the efficacy, safety and cost-effectiveness of preoperative IV iron with placebo in patients with anaemia before elective cardiac surgery.

Sample Size

1000 patients

Study Duration

4 years

Primary Endpoint

Days alive and at home up to 90 days after surgery (DAH90). This endpoint therefore encompasses death, hospital stay, need for ongoing rehabilitation, and re-admission(s). It reflects personal, social and economic benefits of a good recovery after surgery.

Secondary Endpoints

Correction of anaemia (∆Hb) from treatment to day of surgery, red cell transfusions, postoperative complications, ICU and hospital stay, disability-free survival, days alive and at home 30 days after surgery (DAH30) and 90-day mortality. Patient reported quality of life will be assessed by the MacNew Heart Disease Questionnaire and EQ5D, and disability using WHODAS. Patients will be assessed at baseline, before operation, at discharge, Day 30, and at 3 and 6 months after surgery.


NHMRC project grant

Further Information

Contact Sophie Wallace: